Literature DB >> 15863383

Treatment of Epstein-Barr-virus-associated primary CNS B cell lymphoma with allogeneic T-cell immunotherapy and stem-cell transplantation.

Robert F Wynn1, Peter D Arkwright, Tanzina Haque, Maged I Gharib, Gwen Wilkie, Marie Morton-Jones, Dorothy H Crawford.   

Abstract

Entities:  

Mesh：

Year:  2005        PMID： 15863383     DOI： 10.1016/S1470-2045(05)70171-6

Source DB:  PubMed          Journal:  Lancet Oncol        ISSN： 1470-2045            Impact factor:   41.316


× No keyword cloud information.
  15 in total

Review 1.  The interplay between Epstein-Barr virus and the immune system: a rationale for adoptive cell therapy of EBV-related disorders.

Authors:  Anna Merlo; Riccardo Turrini; Riccardo Dolcetti; Debora Martorelli; Elena Muraro; Patrizia Comoli; Antonio Rosato
Journal:  Haematologica       Date:  2010-04-26       Impact factor: 9.941

2.  Immunotherapy for EBV-associated malignancies.

Authors:  Anna Merlo; Riccardo Turrini; Riccardo Dolcetti; Paola Zanovello; Antonio Rosato
Journal:  Int J Hematol       Date:  2011-02-19       Impact factor: 2.490

Review 3.  Virus-Specific T Cells: Current and Future Use in Primary Immunodeficiency Disorders.

Authors:  Katherine M Harris; Blachy J Davila; Catherine M Bollard; Michael D Keller
Journal:  J Allergy Clin Immunol Pract       Date:  2018-12-21

4.  Post-traumatic basal ganglia haemorrhage in a child with primary central nervous system lymphoma.

Authors:  Pawel P Jankowski; Michael L Levy; John Ross Crawford
Journal:  BMJ Case Rep       Date:  2013-07-31

5.  Antiviral T Cells for Adenovirus in the Pretransplant Period: A Bridge Therapy for Severe Combined Immunodeficiency.

Authors:  Holly K Miller; Patrick J Hanley; Haili Lang; Christopher A Lazarski; Elizabeth A Chorvinsky; Sarah McCormack; Lauren Roesch; Shuroug Albihani; Marcus Dean; Fahmida Hoq; Roberta H Adams; Catherine M Bollard; Michael D Keller
Journal:  Biol Blood Marrow Transplant       Date:  2018-05-09       Impact factor: 5.742

6.  Adoptive transfer of allogeneic tumor-specific T cells mediates effective regression of large tumors across major histocompatibility barriers.

Authors:  Andrea Boni; Pawel Muranski; Lydie Cassard; Claudia Wrzesinski; Chrystal M Paulos; Douglas C Palmer; Luca Gattinoni; Christian S Hinrichs; Chi-Chao Chan; Steven A Rosenberg; Nicholas P Restifo
Journal:  Blood       Date:  2008-09-17       Impact factor: 22.113

7.  Alloreactive cytotoxic T cells provide means to decipher the immunopeptidome and reveal a plethora of tumor-associated self-epitopes.

Authors:  Shraddha Kumari; Sébastien Wälchli; Lars-Egil Fallang; Weiwen Yang; Fridtjof Lund-Johansen; Ton N Schumacher; Johanna Olweus
Journal:  Proc Natl Acad Sci U S A       Date:  2013-12-16       Impact factor: 11.205

8.  Adoptive immunotherapy for primary immunodeficiency disorders with virus-specific T lymphocytes.

Authors:  Swati Naik; Sarah K Nicholas; Caridad A Martinez; Ann M Leen; Patrick J Hanley; Steven M Gottschalk; Cliona M Rooney; I Celine Hanson; Robert A Krance; Elizabeth J Shpall; Conrad R Cruz; Persis Amrolia; Giovanna Lucchini; Nancy Bunin; Jennifer Heimall; Orly R Klein; Andrew R Gennery; Mary A Slatter; Mark A Vickers; Jordan S Orange; Helen E Heslop; Catherine M Bollard; Michael D Keller
Journal:  J Allergy Clin Immunol       Date:  2016-02-24       Impact factor: 10.793

Review 9.  Adoptive T Cell Immunotherapy for Patients with Primary Immunodeficiency Disorders.

Authors:  Lauren P McLaughlin; Catherine M Bollard; Michael Keller
Journal:  Curr Allergy Asthma Rep       Date:  2017-01       Impact factor: 4.919

Review 10.  Virus-specific T-cell therapies for patients with primary immune deficiency.

Authors:  Michael D Keller; Catherine M Bollard
Journal:  Blood       Date:  2020-02-27       Impact factor: 25.476
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.